Global Alpha-emitting Radiopharmaceutical Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Alpha-emitting Radiopharmaceutical market size was valued at US$ 227 million in 2025 and is forecast to a readjusted size of US$ 334 million by 2032 with a CAGR of 6.2% during review period.
Alpha-emitting Radiopharmaceuticals are innovative therapeutic radiopharmaceuticals that use alpha-particle-emitting radionuclides as the core cytotoxic payload and deliver them precisely to tumor cells or disease microenvironments through small molecules, antibodies, peptides, ligands, or other targeting vectors. By releasing high-linear-energy-transfer radiation, they can induce double-strand DNA breaks and potent tumor cell killing. Compared with conventional external beam radiotherapy or certain beta-emitting radiopharmaceuticals, alpha particles have a shorter tissue range and higher energy density, enabling strong localized tumor destruction while potentially reducing unnecessary exposure to surrounding healthy tissues. This product category integrates nuclear medicine, targeted oncology, radiochemistry, isotope supply, companion diagnostics, and precision medicine, making it a frontier field in the evolution of radiopharmaceuticals from diagnosis to therapy and from single indications to broader oncology applications.The average gross profit margin of this product is 93%.
Alpha-emitting radiopharmaceuticals are entering a strategic window where nuclear medicine therapy and precision oncology are converging. As the clinical value of radioligand therapy continues to gain recognition globally, pharmaceutical companies, investors, and clinical institutions are showing growing interest in the model of ?diagnosis-guided precision killing.? The core appeal of alpha-emitting radiopharmaceuticals lies in their high energy, short tissue range, and strong ability to induce DNA damage, making them particularly attractive for minimal residual disease, heterogeneous solid tumors, bone metastases, and patient populations resistant to conventional therapies. The active investment of major pharmaceutical companies in radioconjugates, actinium-based platforms, and isotope supply chains is accelerating the field from early-stage research toward industrial competition. For CEOs, marketing leaders, and investors, alpha-emitting radiopharmaceuticals represent not only a new drug category but also a strategic entry point into targeted oncology, nuclear medicine infrastructure, and next-generation precision therapy platforms.
The challenges of alpha-emitting radiopharmaceuticals arise from the combined complexity of technology, regulation, manufacturing, and clinical translation. First, alpha-emitting radionuclides involve demanding requirements related to half-life, decay chains, daughter isotope migration, and radiochemical stability, meaning drug design must simultaneously achieve targeting efficiency, in vivo stability, and a safe therapeutic window. Second, radiopharmaceutical manufacturing requires specialized licenses, shielding facilities, hot cells, automated synthesis modules, radioactive waste management, and stringent GMP systems, creating significantly higher barriers than conventional innovative drugs. Third, clinical implementation depends on close collaboration among nuclear medicine, oncology, imaging, pharmacy, and radiation safety teams, while treatment-center readiness and patient workflow directly shape commercialization speed. At the same time, bone marrow suppression, renal toxicity, salivary gland injury, dosimetry assessment, and long-term safety remain core risks that companies must address seriously during clinical development and market access.
Downstream demand for alpha-emitting radiopharmaceuticals will evolve rapidly around difficult-to-treat cancers, precision patient stratification, and integrated diagnosis-treatment pathways. Oncology hospitals, nuclear medicine departments in general hospitals, prostate cancer centers, neuroendocrine tumor centers, bone metastasis treatment centers, and innovative drug clinical research institutions will become key early-use and market education settings. As PET/SPECT imaging, target testing, molecular profiling, and dosimetry management mature, downstream customers will evaluate these products not only by therapeutic efficacy but also by target selection, imaging confirmation, treatment accessibility, toxicity management, and multidisciplinary workflow efficiency. Future demand will no longer focus simply on whether a new radiopharmaceutical is available, but on whether a complete solution can be built from diagnosis, patient screening, dosing, monitoring, and retreatment. This will give stronger competitive advantages to companies with integrated pipelines, nuclear medicine channels, and treatment-center collaboration capabilities.
This report is a detailed and comprehensive analysis for global Alpha-emitting Radiopharmaceutical market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Alpha-emitting Radiopharmaceutical market size and forecasts, in consumption value ($ Million), 2021-2032
Global Alpha-emitting Radiopharmaceutical market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Alpha-emitting Radiopharmaceutical market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Alpha-emitting Radiopharmaceutical market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Alpha-emitting Radiopharmaceutical market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Alpha-emitting Radiopharmaceuticals are innovative therapeutic radiopharmaceuticals that use alpha-particle-emitting radionuclides as the core cytotoxic payload and deliver them precisely to tumor cells or disease microenvironments through small molecules, antibodies, peptides, ligands, or other targeting vectors. By releasing high-linear-energy-transfer radiation, they can induce double-strand DNA breaks and potent tumor cell killing. Compared with conventional external beam radiotherapy or certain beta-emitting radiopharmaceuticals, alpha particles have a shorter tissue range and higher energy density, enabling strong localized tumor destruction while potentially reducing unnecessary exposure to surrounding healthy tissues. This product category integrates nuclear medicine, targeted oncology, radiochemistry, isotope supply, companion diagnostics, and precision medicine, making it a frontier field in the evolution of radiopharmaceuticals from diagnosis to therapy and from single indications to broader oncology applications.The average gross profit margin of this product is 93%.
Alpha-emitting radiopharmaceuticals are entering a strategic window where nuclear medicine therapy and precision oncology are converging. As the clinical value of radioligand therapy continues to gain recognition globally, pharmaceutical companies, investors, and clinical institutions are showing growing interest in the model of ?diagnosis-guided precision killing.? The core appeal of alpha-emitting radiopharmaceuticals lies in their high energy, short tissue range, and strong ability to induce DNA damage, making them particularly attractive for minimal residual disease, heterogeneous solid tumors, bone metastases, and patient populations resistant to conventional therapies. The active investment of major pharmaceutical companies in radioconjugates, actinium-based platforms, and isotope supply chains is accelerating the field from early-stage research toward industrial competition. For CEOs, marketing leaders, and investors, alpha-emitting radiopharmaceuticals represent not only a new drug category but also a strategic entry point into targeted oncology, nuclear medicine infrastructure, and next-generation precision therapy platforms.
The challenges of alpha-emitting radiopharmaceuticals arise from the combined complexity of technology, regulation, manufacturing, and clinical translation. First, alpha-emitting radionuclides involve demanding requirements related to half-life, decay chains, daughter isotope migration, and radiochemical stability, meaning drug design must simultaneously achieve targeting efficiency, in vivo stability, and a safe therapeutic window. Second, radiopharmaceutical manufacturing requires specialized licenses, shielding facilities, hot cells, automated synthesis modules, radioactive waste management, and stringent GMP systems, creating significantly higher barriers than conventional innovative drugs. Third, clinical implementation depends on close collaboration among nuclear medicine, oncology, imaging, pharmacy, and radiation safety teams, while treatment-center readiness and patient workflow directly shape commercialization speed. At the same time, bone marrow suppression, renal toxicity, salivary gland injury, dosimetry assessment, and long-term safety remain core risks that companies must address seriously during clinical development and market access.
Downstream demand for alpha-emitting radiopharmaceuticals will evolve rapidly around difficult-to-treat cancers, precision patient stratification, and integrated diagnosis-treatment pathways. Oncology hospitals, nuclear medicine departments in general hospitals, prostate cancer centers, neuroendocrine tumor centers, bone metastasis treatment centers, and innovative drug clinical research institutions will become key early-use and market education settings. As PET/SPECT imaging, target testing, molecular profiling, and dosimetry management mature, downstream customers will evaluate these products not only by therapeutic efficacy but also by target selection, imaging confirmation, treatment accessibility, toxicity management, and multidisciplinary workflow efficiency. Future demand will no longer focus simply on whether a new radiopharmaceutical is available, but on whether a complete solution can be built from diagnosis, patient screening, dosing, monitoring, and retreatment. This will give stronger competitive advantages to companies with integrated pipelines, nuclear medicine channels, and treatment-center collaboration capabilities.
This report is a detailed and comprehensive analysis for global Alpha-emitting Radiopharmaceutical market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Alpha-emitting Radiopharmaceutical market size and forecasts, in consumption value ($ Million), 2021-2032
Global Alpha-emitting Radiopharmaceutical market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Alpha-emitting Radiopharmaceutical market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Alpha-emitting Radiopharmaceutical market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Alpha-emitting Radiopharmaceutical
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Alpha-emitting Radiopharmaceutical market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Actinium-225 Radiopharmaceuticals
- Radium-223 Radiopharmaceuticals
- Lead-212 Radiopharmaceuticals
- Astatine-211 Radiopharmaceuticals
- Bismuth-213 Radiopharmaceuticals
- Other
- Prostate Cancer Targeted Agents
- Neuroendocrine Tumor Agents
- Hematologic Malignancy Agents
- Solid Tumor Agents
- Companion Diagnostic Enabled
- Other
- Ready-To-Use Injection
- Radiolabeling Kit
- Isotope Precursor
- Other
- Prostate Cancer
- Bone Metastases
- Neuroendocrine Tumors
- Hematologic Malignancies
- Other Solid Tumors
- Other
- Bayer
- Novartis
- Eli Lilly
- AstraZeneca
- Fusion Pharmaceuticals
- Telix Pharmaceuticals
- RayzeBio
- Orano Med
- Actinium Pharmaceuticals
- Alpha-9 Theranostics
- AdvanCell
- ITM Isotope Technologies Munich
- Curium
- China Isotope & Radiation
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
- Chapter 1, to describe Alpha-emitting Radiopharmaceutical product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top players of Alpha-emitting Radiopharmaceutical, with revenue, gross margin, and global market share of Alpha-emitting Radiopharmaceutical from 2021 to 2026.
- Chapter 3, the Alpha-emitting Radiopharmaceutical competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
- Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Alpha-emitting Radiopharmaceutical market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
- Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
- Chapter 12, the key raw materials and key suppliers, and industry chain of Alpha-emitting Radiopharmaceutical.
- Chapter 13, to describe Alpha-emitting Radiopharmaceutical research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Alpha-emitting Radiopharmaceutical by Type
1.3.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type in 2025
1.3.3 Actinium-225 Radiopharmaceuticals
1.3.4 Radium-223 Radiopharmaceuticals
1.3.5 Lead-212 Radiopharmaceuticals
1.3.6 Astatine-211 Radiopharmaceuticals
1.3.7 Bismuth-213 Radiopharmaceuticals
1.3.8 Other
1.4 Classification of Alpha-emitting Radiopharmaceutical by Indication
1.4.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Indication: 2021 Versus 2025 Versus 2032
1.4.2 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Indication in 2025
1.4.3 Prostate Cancer Targeted Agents
1.4.4 Neuroendocrine Tumor Agents
1.4.5 Hematologic Malignancy Agents
1.4.6 Solid Tumor Agents
1.4.7 Companion Diagnostic Enabled
1.4.8 Other
1.5 Classification of Alpha-emitting Radiopharmaceutical by Supply Form
1.5.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Supply Form: 2021 Versus 2025 Versus 2032
1.5.2 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Supply Form in 2025
1.5.3 Ready-To-Use Injection
1.5.4 Radiolabeling Kit
1.5.5 Isotope Precursor
1.5.6 Other
1.6 Global Alpha-emitting Radiopharmaceutical Market by Application
1.6.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Prostate Cancer
1.6.3 Bone Metastases
1.6.4 Neuroendocrine Tumors
1.6.5 Hematologic Malignancies
1.6.6 Other Solid Tumors
1.6.7 Other
1.7 Global Alpha-emitting Radiopharmaceutical Market Size & Forecast
1.8 Global Alpha-emitting Radiopharmaceutical Market Size and Forecast by Region
1.8.1 Global Alpha-emitting Radiopharmaceutical Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Alpha-emitting Radiopharmaceutical Market Size by Region, (2021-2032)
1.8.3 North America Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.4 Europe Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.6 South America Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Alpha-emitting Radiopharmaceutical Product and Solutions
2.1.4 Bayer Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Alpha-emitting Radiopharmaceutical Product and Solutions
2.2.4 Novartis Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Alpha-emitting Radiopharmaceutical Product and Solutions
2.3.4 Eli Lilly Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Eli Lilly Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Alpha-emitting Radiopharmaceutical Product and Solutions
2.4.4 AstraZeneca Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Fusion Pharmaceuticals
2.5.1 Fusion Pharmaceuticals Details
2.5.2 Fusion Pharmaceuticals Major Business
2.5.3 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
2.5.4 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Fusion Pharmaceuticals Recent Developments and Future Plans
2.6 Telix Pharmaceuticals
2.6.1 Telix Pharmaceuticals Details
2.6.2 Telix Pharmaceuticals Major Business
2.6.3 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
2.6.4 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.7 RayzeBio
2.7.1 RayzeBio Details
2.7.2 RayzeBio Major Business
2.7.3 RayzeBio Alpha-emitting Radiopharmaceutical Product and Solutions
2.7.4 RayzeBio Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 RayzeBio Recent Developments and Future Plans
2.8 Orano Med
2.8.1 Orano Med Details
2.8.2 Orano Med Major Business
2.8.3 Orano Med Alpha-emitting Radiopharmaceutical Product and Solutions
2.8.4 Orano Med Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Orano Med Recent Developments and Future Plans
2.9 Actinium Pharmaceuticals
2.9.1 Actinium Pharmaceuticals Details
2.9.2 Actinium Pharmaceuticals Major Business
2.9.3 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
2.9.4 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.10 Alpha-9 Theranostics
2.10.1 Alpha-9 Theranostics Details
2.10.2 Alpha-9 Theranostics Major Business
2.10.3 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Solutions
2.10.4 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Alpha-9 Theranostics Recent Developments and Future Plans
2.11 AdvanCell
2.11.1 AdvanCell Details
2.11.2 AdvanCell Major Business
2.11.3 AdvanCell Alpha-emitting Radiopharmaceutical Product and Solutions
2.11.4 AdvanCell Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 AdvanCell Recent Developments and Future Plans
2.12 ITM Isotope Technologies Munich
2.12.1 ITM Isotope Technologies Munich Details
2.12.2 ITM Isotope Technologies Munich Major Business
2.12.3 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Solutions
2.12.4 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 ITM Isotope Technologies Munich Recent Developments and Future Plans
2.13 Curium
2.13.1 Curium Details
2.13.2 Curium Major Business
2.13.3 Curium Alpha-emitting Radiopharmaceutical Product and Solutions
2.13.4 Curium Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Curium Recent Developments and Future Plans
2.14 China Isotope & Radiation
2.14.1 China Isotope & Radiation Details
2.14.2 China Isotope & Radiation Major Business
2.14.3 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Solutions
2.14.4 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 China Isotope & Radiation Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Alpha-emitting Radiopharmaceutical Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Alpha-emitting Radiopharmaceutical by Company Revenue
3.2.2 Top 3 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
3.2.3 Top 6 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
3.3 Alpha-emitting Radiopharmaceutical Market: Overall Company Footprint Analysis
3.3.1 Alpha-emitting Radiopharmaceutical Market: Region Footprint
3.3.2 Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
3.3.3 Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Alpha-emitting Radiopharmaceutical Consumption Value and Market Share by Type (2021-2026)
4.2 Global Alpha-emitting Radiopharmaceutical Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2026)
5.2 Global Alpha-emitting Radiopharmaceutical Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
6.2 North America Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2032)
6.3 North America Alpha-emitting Radiopharmaceutical Market Size by Country
6.3.1 North America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
6.3.2 United States Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
6.3.3 Canada Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
6.3.4 Mexico Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
7.2 Europe Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
7.3 Europe Alpha-emitting Radiopharmaceutical Market Size by Country
7.3.1 Europe Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
7.3.2 Germany Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.3 France Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.5 Russia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.6 Italy Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Alpha-emitting Radiopharmaceutical Market Size by Region
8.3.1 Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2032)
8.3.2 China Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.3 Japan Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.4 South Korea Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.5 India Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.7 Australia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
9.2 South America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
9.3 South America Alpha-emitting Radiopharmaceutical Market Size by Country
9.3.1 South America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
9.3.2 Brazil Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
9.3.3 Argentina Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size by Country
10.3.1 Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
10.3.2 Turkey Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
10.3.4 UAE Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Alpha-emitting Radiopharmaceutical Market Drivers
11.2 Alpha-emitting Radiopharmaceutical Market Restraints
11.3 Alpha-emitting Radiopharmaceutical Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Alpha-emitting Radiopharmaceutical Industry Chain
12.2 Alpha-emitting Radiopharmaceutical Upstream Analysis
12.3 Alpha-emitting Radiopharmaceutical Midstream Analysis
12.4 Alpha-emitting Radiopharmaceutical Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Alpha-emitting Radiopharmaceutical by Type
1.3.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type in 2025
1.3.3 Actinium-225 Radiopharmaceuticals
1.3.4 Radium-223 Radiopharmaceuticals
1.3.5 Lead-212 Radiopharmaceuticals
1.3.6 Astatine-211 Radiopharmaceuticals
1.3.7 Bismuth-213 Radiopharmaceuticals
1.3.8 Other
1.4 Classification of Alpha-emitting Radiopharmaceutical by Indication
1.4.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Indication: 2021 Versus 2025 Versus 2032
1.4.2 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Indication in 2025
1.4.3 Prostate Cancer Targeted Agents
1.4.4 Neuroendocrine Tumor Agents
1.4.5 Hematologic Malignancy Agents
1.4.6 Solid Tumor Agents
1.4.7 Companion Diagnostic Enabled
1.4.8 Other
1.5 Classification of Alpha-emitting Radiopharmaceutical by Supply Form
1.5.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Supply Form: 2021 Versus 2025 Versus 2032
1.5.2 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Supply Form in 2025
1.5.3 Ready-To-Use Injection
1.5.4 Radiolabeling Kit
1.5.5 Isotope Precursor
1.5.6 Other
1.6 Global Alpha-emitting Radiopharmaceutical Market by Application
1.6.1 Overview: Global Alpha-emitting Radiopharmaceutical Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Prostate Cancer
1.6.3 Bone Metastases
1.6.4 Neuroendocrine Tumors
1.6.5 Hematologic Malignancies
1.6.6 Other Solid Tumors
1.6.7 Other
1.7 Global Alpha-emitting Radiopharmaceutical Market Size & Forecast
1.8 Global Alpha-emitting Radiopharmaceutical Market Size and Forecast by Region
1.8.1 Global Alpha-emitting Radiopharmaceutical Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Alpha-emitting Radiopharmaceutical Market Size by Region, (2021-2032)
1.8.3 North America Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.4 Europe Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.6 South America Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Alpha-emitting Radiopharmaceutical Product and Solutions
2.1.4 Bayer Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Alpha-emitting Radiopharmaceutical Product and Solutions
2.2.4 Novartis Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Alpha-emitting Radiopharmaceutical Product and Solutions
2.3.4 Eli Lilly Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Eli Lilly Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Alpha-emitting Radiopharmaceutical Product and Solutions
2.4.4 AstraZeneca Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Fusion Pharmaceuticals
2.5.1 Fusion Pharmaceuticals Details
2.5.2 Fusion Pharmaceuticals Major Business
2.5.3 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
2.5.4 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Fusion Pharmaceuticals Recent Developments and Future Plans
2.6 Telix Pharmaceuticals
2.6.1 Telix Pharmaceuticals Details
2.6.2 Telix Pharmaceuticals Major Business
2.6.3 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
2.6.4 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.7 RayzeBio
2.7.1 RayzeBio Details
2.7.2 RayzeBio Major Business
2.7.3 RayzeBio Alpha-emitting Radiopharmaceutical Product and Solutions
2.7.4 RayzeBio Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 RayzeBio Recent Developments and Future Plans
2.8 Orano Med
2.8.1 Orano Med Details
2.8.2 Orano Med Major Business
2.8.3 Orano Med Alpha-emitting Radiopharmaceutical Product and Solutions
2.8.4 Orano Med Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Orano Med Recent Developments and Future Plans
2.9 Actinium Pharmaceuticals
2.9.1 Actinium Pharmaceuticals Details
2.9.2 Actinium Pharmaceuticals Major Business
2.9.3 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
2.9.4 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.10 Alpha-9 Theranostics
2.10.1 Alpha-9 Theranostics Details
2.10.2 Alpha-9 Theranostics Major Business
2.10.3 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Solutions
2.10.4 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Alpha-9 Theranostics Recent Developments and Future Plans
2.11 AdvanCell
2.11.1 AdvanCell Details
2.11.2 AdvanCell Major Business
2.11.3 AdvanCell Alpha-emitting Radiopharmaceutical Product and Solutions
2.11.4 AdvanCell Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 AdvanCell Recent Developments and Future Plans
2.12 ITM Isotope Technologies Munich
2.12.1 ITM Isotope Technologies Munich Details
2.12.2 ITM Isotope Technologies Munich Major Business
2.12.3 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Solutions
2.12.4 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 ITM Isotope Technologies Munich Recent Developments and Future Plans
2.13 Curium
2.13.1 Curium Details
2.13.2 Curium Major Business
2.13.3 Curium Alpha-emitting Radiopharmaceutical Product and Solutions
2.13.4 Curium Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Curium Recent Developments and Future Plans
2.14 China Isotope & Radiation
2.14.1 China Isotope & Radiation Details
2.14.2 China Isotope & Radiation Major Business
2.14.3 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Solutions
2.14.4 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 China Isotope & Radiation Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Alpha-emitting Radiopharmaceutical Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Alpha-emitting Radiopharmaceutical by Company Revenue
3.2.2 Top 3 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
3.2.3 Top 6 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
3.3 Alpha-emitting Radiopharmaceutical Market: Overall Company Footprint Analysis
3.3.1 Alpha-emitting Radiopharmaceutical Market: Region Footprint
3.3.2 Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
3.3.3 Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Alpha-emitting Radiopharmaceutical Consumption Value and Market Share by Type (2021-2026)
4.2 Global Alpha-emitting Radiopharmaceutical Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2026)
5.2 Global Alpha-emitting Radiopharmaceutical Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
6.2 North America Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2032)
6.3 North America Alpha-emitting Radiopharmaceutical Market Size by Country
6.3.1 North America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
6.3.2 United States Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
6.3.3 Canada Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
6.3.4 Mexico Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
7.2 Europe Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
7.3 Europe Alpha-emitting Radiopharmaceutical Market Size by Country
7.3.1 Europe Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
7.3.2 Germany Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.3 France Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.5 Russia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
7.3.6 Italy Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Alpha-emitting Radiopharmaceutical Market Size by Region
8.3.1 Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2032)
8.3.2 China Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.3 Japan Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.4 South Korea Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.5 India Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
8.3.7 Australia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
9.2 South America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
9.3 South America Alpha-emitting Radiopharmaceutical Market Size by Country
9.3.1 South America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
9.3.2 Brazil Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
9.3.3 Argentina Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size by Country
10.3.1 Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2032)
10.3.2 Turkey Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
10.3.4 UAE Alpha-emitting Radiopharmaceutical Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Alpha-emitting Radiopharmaceutical Market Drivers
11.2 Alpha-emitting Radiopharmaceutical Market Restraints
11.3 Alpha-emitting Radiopharmaceutical Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Alpha-emitting Radiopharmaceutical Industry Chain
12.2 Alpha-emitting Radiopharmaceutical Upstream Analysis
12.3 Alpha-emitting Radiopharmaceutical Midstream Analysis
12.4 Alpha-emitting Radiopharmaceutical Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Alpha-emitting Radiopharmaceutical Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Alpha-emitting Radiopharmaceutical Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 3. Global Alpha-emitting Radiopharmaceutical Consumption Value by Supply Form, (USD Million), 2021 & 2025 & 2032
Table 4. Global Alpha-emitting Radiopharmaceutical Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Alpha-emitting Radiopharmaceutical Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Bayer Company Information, Head Office, and Major Competitors
Table 8. Bayer Major Business
Table 9. Bayer Alpha-emitting Radiopharmaceutical Product and Solutions
Table 10. Bayer Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Bayer Recent Developments and Future Plans
Table 12. Novartis Company Information, Head Office, and Major Competitors
Table 13. Novartis Major Business
Table 14. Novartis Alpha-emitting Radiopharmaceutical Product and Solutions
Table 15. Novartis Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Novartis Recent Developments and Future Plans
Table 17. Eli Lilly Company Information, Head Office, and Major Competitors
Table 18. Eli Lilly Major Business
Table 19. Eli Lilly Alpha-emitting Radiopharmaceutical Product and Solutions
Table 20. Eli Lilly Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. AstraZeneca Company Information, Head Office, and Major Competitors
Table 22. AstraZeneca Major Business
Table 23. AstraZeneca Alpha-emitting Radiopharmaceutical Product and Solutions
Table 24. AstraZeneca Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. AstraZeneca Recent Developments and Future Plans
Table 26. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 27. Fusion Pharmaceuticals Major Business
Table 28. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
Table 29. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 31. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 32. Telix Pharmaceuticals Major Business
Table 33. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
Table 34. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Telix Pharmaceuticals Recent Developments and Future Plans
Table 36. RayzeBio Company Information, Head Office, and Major Competitors
Table 37. RayzeBio Major Business
Table 38. RayzeBio Alpha-emitting Radiopharmaceutical Product and Solutions
Table 39. RayzeBio Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. RayzeBio Recent Developments and Future Plans
Table 41. Orano Med Company Information, Head Office, and Major Competitors
Table 42. Orano Med Major Business
Table 43. Orano Med Alpha-emitting Radiopharmaceutical Product and Solutions
Table 44. Orano Med Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Orano Med Recent Developments and Future Plans
Table 46. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 47. Actinium Pharmaceuticals Major Business
Table 48. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
Table 49. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 51. Alpha-9 Theranostics Company Information, Head Office, and Major Competitors
Table 52. Alpha-9 Theranostics Major Business
Table 53. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Solutions
Table 54. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Alpha-9 Theranostics Recent Developments and Future Plans
Table 56. AdvanCell Company Information, Head Office, and Major Competitors
Table 57. AdvanCell Major Business
Table 58. AdvanCell Alpha-emitting Radiopharmaceutical Product and Solutions
Table 59. AdvanCell Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. AdvanCell Recent Developments and Future Plans
Table 61. ITM Isotope Technologies Munich Company Information, Head Office, and Major Competitors
Table 62. ITM Isotope Technologies Munich Major Business
Table 63. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Solutions
Table 64. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. ITM Isotope Technologies Munich Recent Developments and Future Plans
Table 66. Curium Company Information, Head Office, and Major Competitors
Table 67. Curium Major Business
Table 68. Curium Alpha-emitting Radiopharmaceutical Product and Solutions
Table 69. Curium Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Curium Recent Developments and Future Plans
Table 71. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 72. China Isotope & Radiation Major Business
Table 73. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Solutions
Table 74. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. China Isotope & Radiation Recent Developments and Future Plans
Table 76. Global Alpha-emitting Radiopharmaceutical Revenue (USD Million) by Players (2021-2026)
Table 77. Global Alpha-emitting Radiopharmaceutical Revenue Share by Players (2021-2026)
Table 78. Breakdown of Alpha-emitting Radiopharmaceutical by Company Type (Tier 1, Tier 2, and Tier 3)
Table 79. Market Position of Players in Alpha-emitting Radiopharmaceutical, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 80. Head Office of Key Alpha-emitting Radiopharmaceutical Players
Table 81. Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
Table 82. Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
Table 83. Alpha-emitting Radiopharmaceutical New Market Entrants and Barriers to Market Entry
Table 84. Alpha-emitting Radiopharmaceutical Mergers, Acquisition, Agreements, and Collaborations
Table 85. Global Alpha-emitting Radiopharmaceutical Consumption Value (USD Million) by Type (2021-2026)
Table 86. Global Alpha-emitting Radiopharmaceutical Consumption Value Share by Type (2021-2026)
Table 87. Global Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Type (2027-2032)
Table 88. Global Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026)
Table 89. Global Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Application (2027-2032)
Table 90. North America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 91. North America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 92. North America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 93. North America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 94. North America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 95. North America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 96. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 97. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 98. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 99. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 100. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 101. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 102. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 103. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 104. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 105. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 106. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026) & (USD Million)
Table 107. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Region (2027-2032) & (USD Million)
Table 108. South America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 109. South America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 110. South America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 111. South America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 112. South America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 113. South America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 114. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 115. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 116. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 117. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 118. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 119. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 120. Global Key Players of Alpha-emitting Radiopharmaceutical Upstream (Raw Materials)
Table 121. Global Alpha-emitting Radiopharmaceutical Typical Customers
Table 1. Global Alpha-emitting Radiopharmaceutical Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Alpha-emitting Radiopharmaceutical Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 3. Global Alpha-emitting Radiopharmaceutical Consumption Value by Supply Form, (USD Million), 2021 & 2025 & 2032
Table 4. Global Alpha-emitting Radiopharmaceutical Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Alpha-emitting Radiopharmaceutical Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Bayer Company Information, Head Office, and Major Competitors
Table 8. Bayer Major Business
Table 9. Bayer Alpha-emitting Radiopharmaceutical Product and Solutions
Table 10. Bayer Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Bayer Recent Developments and Future Plans
Table 12. Novartis Company Information, Head Office, and Major Competitors
Table 13. Novartis Major Business
Table 14. Novartis Alpha-emitting Radiopharmaceutical Product and Solutions
Table 15. Novartis Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Novartis Recent Developments and Future Plans
Table 17. Eli Lilly Company Information, Head Office, and Major Competitors
Table 18. Eli Lilly Major Business
Table 19. Eli Lilly Alpha-emitting Radiopharmaceutical Product and Solutions
Table 20. Eli Lilly Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. AstraZeneca Company Information, Head Office, and Major Competitors
Table 22. AstraZeneca Major Business
Table 23. AstraZeneca Alpha-emitting Radiopharmaceutical Product and Solutions
Table 24. AstraZeneca Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. AstraZeneca Recent Developments and Future Plans
Table 26. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 27. Fusion Pharmaceuticals Major Business
Table 28. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
Table 29. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 31. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 32. Telix Pharmaceuticals Major Business
Table 33. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
Table 34. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Telix Pharmaceuticals Recent Developments and Future Plans
Table 36. RayzeBio Company Information, Head Office, and Major Competitors
Table 37. RayzeBio Major Business
Table 38. RayzeBio Alpha-emitting Radiopharmaceutical Product and Solutions
Table 39. RayzeBio Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. RayzeBio Recent Developments and Future Plans
Table 41. Orano Med Company Information, Head Office, and Major Competitors
Table 42. Orano Med Major Business
Table 43. Orano Med Alpha-emitting Radiopharmaceutical Product and Solutions
Table 44. Orano Med Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Orano Med Recent Developments and Future Plans
Table 46. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 47. Actinium Pharmaceuticals Major Business
Table 48. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product and Solutions
Table 49. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 51. Alpha-9 Theranostics Company Information, Head Office, and Major Competitors
Table 52. Alpha-9 Theranostics Major Business
Table 53. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product and Solutions
Table 54. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Alpha-9 Theranostics Recent Developments and Future Plans
Table 56. AdvanCell Company Information, Head Office, and Major Competitors
Table 57. AdvanCell Major Business
Table 58. AdvanCell Alpha-emitting Radiopharmaceutical Product and Solutions
Table 59. AdvanCell Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. AdvanCell Recent Developments and Future Plans
Table 61. ITM Isotope Technologies Munich Company Information, Head Office, and Major Competitors
Table 62. ITM Isotope Technologies Munich Major Business
Table 63. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product and Solutions
Table 64. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. ITM Isotope Technologies Munich Recent Developments and Future Plans
Table 66. Curium Company Information, Head Office, and Major Competitors
Table 67. Curium Major Business
Table 68. Curium Alpha-emitting Radiopharmaceutical Product and Solutions
Table 69. Curium Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Curium Recent Developments and Future Plans
Table 71. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 72. China Isotope & Radiation Major Business
Table 73. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product and Solutions
Table 74. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. China Isotope & Radiation Recent Developments and Future Plans
Table 76. Global Alpha-emitting Radiopharmaceutical Revenue (USD Million) by Players (2021-2026)
Table 77. Global Alpha-emitting Radiopharmaceutical Revenue Share by Players (2021-2026)
Table 78. Breakdown of Alpha-emitting Radiopharmaceutical by Company Type (Tier 1, Tier 2, and Tier 3)
Table 79. Market Position of Players in Alpha-emitting Radiopharmaceutical, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 80. Head Office of Key Alpha-emitting Radiopharmaceutical Players
Table 81. Alpha-emitting Radiopharmaceutical Market: Company Product Type Footprint
Table 82. Alpha-emitting Radiopharmaceutical Market: Company Product Application Footprint
Table 83. Alpha-emitting Radiopharmaceutical New Market Entrants and Barriers to Market Entry
Table 84. Alpha-emitting Radiopharmaceutical Mergers, Acquisition, Agreements, and Collaborations
Table 85. Global Alpha-emitting Radiopharmaceutical Consumption Value (USD Million) by Type (2021-2026)
Table 86. Global Alpha-emitting Radiopharmaceutical Consumption Value Share by Type (2021-2026)
Table 87. Global Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Type (2027-2032)
Table 88. Global Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026)
Table 89. Global Alpha-emitting Radiopharmaceutical Consumption Value Forecast by Application (2027-2032)
Table 90. North America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 91. North America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 92. North America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 93. North America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 94. North America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 95. North America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 96. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 97. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 98. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 99. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 100. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 101. Europe Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 102. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 103. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 104. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 105. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 106. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Region (2021-2026) & (USD Million)
Table 107. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value by Region (2027-2032) & (USD Million)
Table 108. South America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 109. South America Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 110. South America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 111. South America Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 112. South America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 113. South America Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 114. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Type (2021-2026) & (USD Million)
Table 115. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Type (2027-2032) & (USD Million)
Table 116. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Application (2021-2026) & (USD Million)
Table 117. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Application (2027-2032) & (USD Million)
Table 118. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Country (2021-2026) & (USD Million)
Table 119. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value by Country (2027-2032) & (USD Million)
Table 120. Global Key Players of Alpha-emitting Radiopharmaceutical Upstream (Raw Materials)
Table 121. Global Alpha-emitting Radiopharmaceutical Typical Customers
LIST OF FIGURES
Figure 1. Alpha-emitting Radiopharmaceutical Picture
Figure 2. Global Alpha-emitting Radiopharmaceutical Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type in 2025
Figure 4. Actinium-225 Radiopharmaceuticals
Figure 5. Radium-223 Radiopharmaceuticals
Figure 6. Lead-212 Radiopharmaceuticals
Figure 7. Astatine-211 Radiopharmaceuticals
Figure 8. Bismuth-213 Radiopharmaceuticals
Figure 9. Other
Figure 10. Global Alpha-emitting Radiopharmaceutical Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Indication in 2025
Figure 12. Prostate Cancer Targeted Agents
Figure 13. Neuroendocrine Tumor Agents
Figure 14. Hematologic Malignancy Agents
Figure 15. Solid Tumor Agents
Figure 16. Companion Diagnostic Enabled
Figure 17. Other
Figure 18. Global Alpha-emitting Radiopharmaceutical Consumption Value by Supply Form, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Supply Form in 2025
Figure 20. Ready-To-Use Injection
Figure 21. Radiolabeling Kit
Figure 22. Isotope Precursor
Figure 23. Other
Figure 24. Global Alpha-emitting Radiopharmaceutical Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 25. Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application in 2025
Figure 26. Prostate Cancer Picture
Figure 27. Bone Metastases Picture
Figure 28. Neuroendocrine Tumors Picture
Figure 29. Hematologic Malignancies Picture
Figure 30. Other Solid Tumors Picture
Figure 31. Other Picture
Figure 32. Global Alpha-emitting Radiopharmaceutical Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 33. Global Alpha-emitting Radiopharmaceutical Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 34. Global Market Alpha-emitting Radiopharmaceutical Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 35. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region (2021-2032)
Figure 36. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region in 2025
Figure 37. North America Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 39. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 40. South America Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 41. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 42. Company Three Recent Developments and Future Plans
Figure 43. Global Alpha-emitting Radiopharmaceutical Revenue Share by Players in 2025
Figure 44. Alpha-emitting Radiopharmaceutical Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 45. Market Share of Alpha-emitting Radiopharmaceutical by Player Revenue in 2025
Figure 46. Top 3 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
Figure 47. Top 6 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
Figure 48. Global Alpha-emitting Radiopharmaceutical Consumption Value Share by Type (2021-2026)
Figure 49. Global Alpha-emitting Radiopharmaceutical Market Share Forecast by Type (2027-2032)
Figure 50. Global Alpha-emitting Radiopharmaceutical Consumption Value Share by Application (2021-2026)
Figure 51. Global Alpha-emitting Radiopharmaceutical Market Share Forecast by Application (2027-2032)
Figure 52. North America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 53. North America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 54. North America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 55. United States Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 56. Canada Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 57. Mexico Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 58. Europe Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 59. Europe Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 60. Europe Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 61. Germany Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 62. France Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 63. United Kingdom Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 64. Russia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 65. Italy Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 66. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 67. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 68. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region (2021-2032)
Figure 69. China Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 70. Japan Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 71. South Korea Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 72. India Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 73. Southeast Asia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 74. Australia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 75. South America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 76. South America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 77. South America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 78. Brazil Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 79. Argentina Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 80. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 81. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 82. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 83. Turkey Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 84. Saudi Arabia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 85. UAE Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 86. Alpha-emitting Radiopharmaceutical Market Drivers
Figure 87. Alpha-emitting Radiopharmaceutical Market Restraints
Figure 88. Alpha-emitting Radiopharmaceutical Market Trends
Figure 89. Porters Five Forces Analysis
Figure 90. Alpha-emitting Radiopharmaceutical Industrial Chain
Figure 91. Methodology
Figure 92. Research Process and Data Source
Figure 1. Alpha-emitting Radiopharmaceutical Picture
Figure 2. Global Alpha-emitting Radiopharmaceutical Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type in 2025
Figure 4. Actinium-225 Radiopharmaceuticals
Figure 5. Radium-223 Radiopharmaceuticals
Figure 6. Lead-212 Radiopharmaceuticals
Figure 7. Astatine-211 Radiopharmaceuticals
Figure 8. Bismuth-213 Radiopharmaceuticals
Figure 9. Other
Figure 10. Global Alpha-emitting Radiopharmaceutical Consumption Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Indication in 2025
Figure 12. Prostate Cancer Targeted Agents
Figure 13. Neuroendocrine Tumor Agents
Figure 14. Hematologic Malignancy Agents
Figure 15. Solid Tumor Agents
Figure 16. Companion Diagnostic Enabled
Figure 17. Other
Figure 18. Global Alpha-emitting Radiopharmaceutical Consumption Value by Supply Form, (USD Million), 2021 & 2025 & 2032
Figure 19. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Supply Form in 2025
Figure 20. Ready-To-Use Injection
Figure 21. Radiolabeling Kit
Figure 22. Isotope Precursor
Figure 23. Other
Figure 24. Global Alpha-emitting Radiopharmaceutical Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 25. Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application in 2025
Figure 26. Prostate Cancer Picture
Figure 27. Bone Metastases Picture
Figure 28. Neuroendocrine Tumors Picture
Figure 29. Hematologic Malignancies Picture
Figure 30. Other Solid Tumors Picture
Figure 31. Other Picture
Figure 32. Global Alpha-emitting Radiopharmaceutical Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 33. Global Alpha-emitting Radiopharmaceutical Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 34. Global Market Alpha-emitting Radiopharmaceutical Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 35. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region (2021-2032)
Figure 36. Global Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region in 2025
Figure 37. North America Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 39. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 40. South America Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 41. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 42. Company Three Recent Developments and Future Plans
Figure 43. Global Alpha-emitting Radiopharmaceutical Revenue Share by Players in 2025
Figure 44. Alpha-emitting Radiopharmaceutical Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 45. Market Share of Alpha-emitting Radiopharmaceutical by Player Revenue in 2025
Figure 46. Top 3 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
Figure 47. Top 6 Alpha-emitting Radiopharmaceutical Players Market Share in 2025
Figure 48. Global Alpha-emitting Radiopharmaceutical Consumption Value Share by Type (2021-2026)
Figure 49. Global Alpha-emitting Radiopharmaceutical Market Share Forecast by Type (2027-2032)
Figure 50. Global Alpha-emitting Radiopharmaceutical Consumption Value Share by Application (2021-2026)
Figure 51. Global Alpha-emitting Radiopharmaceutical Market Share Forecast by Application (2027-2032)
Figure 52. North America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 53. North America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 54. North America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 55. United States Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 56. Canada Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 57. Mexico Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 58. Europe Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 59. Europe Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 60. Europe Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 61. Germany Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 62. France Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 63. United Kingdom Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 64. Russia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 65. Italy Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 66. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 67. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 68. Asia-Pacific Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Region (2021-2032)
Figure 69. China Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 70. Japan Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 71. South Korea Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 72. India Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 73. Southeast Asia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 74. Australia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 75. South America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 76. South America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 77. South America Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 78. Brazil Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 79. Argentina Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 80. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Type (2021-2032)
Figure 81. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Application (2021-2032)
Figure 82. Middle East & Africa Alpha-emitting Radiopharmaceutical Consumption Value Market Share by Country (2021-2032)
Figure 83. Turkey Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 84. Saudi Arabia Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 85. UAE Alpha-emitting Radiopharmaceutical Consumption Value (2021-2032) & (USD Million)
Figure 86. Alpha-emitting Radiopharmaceutical Market Drivers
Figure 87. Alpha-emitting Radiopharmaceutical Market Restraints
Figure 88. Alpha-emitting Radiopharmaceutical Market Trends
Figure 89. Porters Five Forces Analysis
Figure 90. Alpha-emitting Radiopharmaceutical Industrial Chain
Figure 91. Methodology
Figure 92. Research Process and Data Source
